Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes

Background: Autoimmune hemolytic anemia (AIHA) is an uncommon disease. In its presentation, it can be severe and even lethal. There is only one clinical report concerning this pathology in Chile. Objective: To describe the clinical characteristics and evolution of adult AIHA inpatients. Materials...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	López-Vidal,Hernán, Peña,Camila, Gajardo,Claudia, Valladares,Ximena, Cabrera C.,María Elena
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Autoimmune Diseases Autoantibodies Anemia, Hemolytic, Autoimmune Rituximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000700836
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000700836
record_format	dspace
spelling	oai:scielo:S0034-988720190007008362019-11-04Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientesLópez-Vidal,HernánPeña,CamilaGajardo,ClaudiaValladares,XimenaCabrera C.,María Elena Autoimmune Diseases Autoantibodies Anemia, Hemolytic, Autoimmune Rituximab Background: Autoimmune hemolytic anemia (AIHA) is an uncommon disease. In its presentation, it can be severe and even lethal. There is only one clinical report concerning this pathology in Chile. Objective: To describe the clinical characteristics and evolution of adult AIHA inpatients. Materials and Methods: Retrospective review of clinical records of adult AIHA inpatients between January 2010 and June 2018 was done. Demographic, clinical, laboratory and therapeutic information was analyzed. A descriptive, analytical and survival analysis was performed. Results: Forty-three adult patients diagnosed with AHIA were hospitalized in a period of 8 years. Median age was 63 years (range 22-86 years), mostly women (72%). Warm antibodies were detected in 36 cases (84%) and cold antibodies in seven. Seventy two percent of the patients had an underlying cause, and 58% were secondary to lymphoproliferative neoplasms. All patients except two, received steroids as initial treatment, with response in 37 (90%) of them. Three refractory patients received rituximab, with response in all of them, and relapse in one. Median follow-up was 38 months (range 2-98 months). Five year overall survival was 72%. Conclusion: AHIA in adults inpatients is a heterogeneous disease, mainly due to warm antibodies, and to secondary etiology.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.7 20192019-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000700836es10.4067/S0034-98872019000700836
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Autoimmune Diseases Autoantibodies Anemia, Hemolytic, Autoimmune Rituximab
spellingShingle	Autoimmune Diseases Autoantibodies Anemia, Hemolytic, Autoimmune Rituximab López-Vidal,Hernán Peña,Camila Gajardo,Claudia Valladares,Ximena Cabrera C.,María Elena Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
description	Background: Autoimmune hemolytic anemia (AIHA) is an uncommon disease. In its presentation, it can be severe and even lethal. There is only one clinical report concerning this pathology in Chile. Objective: To describe the clinical characteristics and evolution of adult AIHA inpatients. Materials and Methods: Retrospective review of clinical records of adult AIHA inpatients between January 2010 and June 2018 was done. Demographic, clinical, laboratory and therapeutic information was analyzed. A descriptive, analytical and survival analysis was performed. Results: Forty-three adult patients diagnosed with AHIA were hospitalized in a period of 8 years. Median age was 63 years (range 22-86 years), mostly women (72%). Warm antibodies were detected in 36 cases (84%) and cold antibodies in seven. Seventy two percent of the patients had an underlying cause, and 58% were secondary to lymphoproliferative neoplasms. All patients except two, received steroids as initial treatment, with response in 37 (90%) of them. Three refractory patients received rituximab, with response in all of them, and relapse in one. Median follow-up was 38 months (range 2-98 months). Five year overall survival was 72%. Conclusion: AHIA in adults inpatients is a heterogeneous disease, mainly due to warm antibodies, and to secondary etiology.
author	López-Vidal,Hernán Peña,Camila Gajardo,Claudia Valladares,Ximena Cabrera C.,María Elena
author_facet	López-Vidal,Hernán Peña,Camila Gajardo,Claudia Valladares,Ximena Cabrera C.,María Elena
author_sort	López-Vidal,Hernán
title	Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
title_short	Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
title_full	Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
title_fullStr	Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
title_full_unstemmed	Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes
title_sort	anemia hemolítica autoinmune en chile: un análisis retrospectivo de 43 pacientes
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000700836
work_keys_str_mv	AT lopezvidalhernan anemiahemoliticaautoinmuneenchileunanalisisretrospectivode43pacientes AT penacamila anemiahemoliticaautoinmuneenchileunanalisisretrospectivode43pacientes AT gajardoclaudia anemiahemoliticaautoinmuneenchileunanalisisretrospectivode43pacientes AT valladaresximena anemiahemoliticaautoinmuneenchileunanalisisretrospectivode43pacientes AT cabreracmariaelena anemiahemoliticaautoinmuneenchileunanalisisretrospectivode43pacientes
_version_	1718437071350136832

Anemia hemolítica autoinmune en Chile: un análisis retrospectivo de 43 pacientes

Ejemplares similares